Biogen Inc. Common Stock (BIIB) fair value

ACCE thesis

Biogen sells multiple sclerosis drugs (Tecfidera, Tysabri, Vumerity), spinal muscular atrophy therapy Spinraza, and Leqembi, its Alzheimer's antibody developed with Eisai, and it is trying to shift revenue toward these newer products as its legacy MS franchise erodes. The stock is worth a closer look because the gap between trailing and forward earnings is large: a trailing P/E of 41.3 against a forward P/E of 13.9 implies the market expects a sharp earnings recovery, and the reported 78.3% gross margin and 25.1% operating margin show the business earns well on what it sells. Revenue growth of 3.4% and a 4.6% ROE are modest, so the thesis rests on whether Leqembi and Spinraza can grow fast enough to offset MS erosion. The key diligence question is the pace of Leqembi uptake and whether the forward earnings estimates hold, since that is where the valuation case lives. At a $34.4B market cap with no index membership, the name sits outside the mainstream large-cap healthcare screen, which may partly explain the valuation gap. The 63/100 score is a middling reading, so this warrants a deeper look at the pipeline and reimbursement trends rather than a conclusion either way.